<DOC>
	<DOCNO>NCT01324960</DOCNO>
	<brief_summary>A phase I study azacitidine Ceplene/interleukin-2 first evaluate safety tolerability regimen patient high risk myelodysplastic syndrome ( MDS ) achieve hematological response 6 cycle azacitidine . After approval independent Data Safety Monitoring Board ( DSMB ) , phase I study follow open label randomize phase II study design characterize efficacy , safety , tolerability addition Ceplene/interleukin-2 azacytidine patient high risk myelodysplastic syndrome ( MDS ) achieve hematological response 6 cycle azacitidine .</brief_summary>
	<brief_title>Azacitidine With Without Ceplene/Interleukin-2 Patients With Higher Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine phosphate</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Age ≥ 18 year Must understand voluntarily sign informed consent form Must able adhere study visit schedule protocol requirement Documented diagnosis MDS accord WHO classification , meet IPSS criterion intermediate2 highrisk disease Must achieve response ( CR , PR , mCR HI accord IWG 2006 criterion ) 6 cycle Azacitidine . Patients must ECOG performance status ( PS ) 0 2 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must negative serum urine pregnancy test within 2 week prior begin treatment study . Nursing patient exclude . Creatinine clearance &gt; 50 ml/min Serum aspartate aminotransferase ( AST ) /serum glutamicoxaloacetic transaminase ( SGOT ) alanine transaminase ( ALT ) /serum glutamate pyruvate transaminase ( SGPT ) &lt; 3.0 x upper limit normal ( ULN ) Serum total bilirubin &lt; 1.5 mg/dL . ( except unconjugated hyperbilirubinemia due Gilbert 's disease secondary MDS ) . Known positive status human immunodeficiency virus ( HIV ) hepatitis B C Uncontrolled intercurrent illness include , limited uncontrolled infection , symptomatic congestive heart failure , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Patients receive standard investigational cytotoxic treatment hematologic malignancy Any medical condition opinion investigator place patient unacceptably high risk toxicity Prior history malignancy MDS ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) unless subject free disease ≥ 3 year Class III IV cardiac disease , hypotension severe hypertension , vasomotor instability , serious uncontrolled cardiac dysrhythmias ( include ventricular arrhythmia ) time , acute myocardial infarction within past 12 month , active uncontrolled angina pectoris symptomatic arteriosclerotic blood vessel disease History seizures , central nervous disorder , stroke within last 12 month , psychiatric disability think clinically significant opinion investigator Prior history autoimmune disease ( include limit systemic lupus , inflammatory bowel disease , psoriasis ) Patients active peptic esophageal ulcer disease past peptic ulcer esophageal disease history bleed Patients continue systemic treatment clonidine , steroid , and/or H2 receptor block agent Patients history hypersensitivity histamine histamine product , severe allergy food contrast medium require treatment within last five year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>IPSS</keyword>
	<keyword>High risk</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>Ceplene</keyword>
</DOC>